Skip to main content
Premium Trial:

Request an Annual Quote

Allegro Dx Licenses IP from BU, University of Utah Foundation for Lung Cancer Test


By Justin Petrone

Allegro Diagnostics this week announced an exclusive license agreement with Boston University and the University of Utah Foundation for intellectual property related to its molecular testing platform.

Called BronchoGen, Allegro's test is manufactured by Affymetrix, and relies on an 80-gene biomarker signature to detect and rule out the presence of lung cancer using histologically normal large-airway epithelial cells obtained at bronchoscopy from smokers suspected to have the disease. The company believes its test can be used in combination with standard bronchoscopy to achieve a diagnosis.

Allegro CEO Mike Webb said in a statement that the licensing agreement will support the "continued advancement" of BronchoGen, including a planned commercial launch in the first half of 2012. Webb was named president and CEO of the Maynard, Mass.-based firm earlier this month (BAN 6/21/2011).

Avrum Spira, director of the Clinical and Translational Science Institute at BU, said in a statement that BU was "pleased" to license technology that "may enable the early detection of lung cancer." Spira co-founded Allegro with fellow BU investigator Jerome Brody in 2006. Dan Rippy, the firm's previous CEO, told BioArray News last year that the company hoped to the debut test in 2010 (BAN 1/5/2010).

Financial terms of the licensing agreement were not disclosed.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.